Can a smartphone app fight chemobrain? new trial aims to find out
NCT ID NCT05864274
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a mobile cognitive training app can reduce 'chemobrain'—memory and thinking problems caused by chemotherapy—in people with gynecologic cancers. Sixty-four participants will use the app on their own phones while undergoing chemotherapy and complete thinking tests. The goal is to see if this simple, at-home tool can help ease these common side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cognitive training application
- What this could lead to
- If it works, this could offer a simple, at-home way to reduce memory and thinking problems during chemotherapy.
- What could go wrong
- This is a small, early study with no placebo group, so results may not be conclusive. The app may not help everyone, and benefits could be minor.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 64 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria are: * newly diagnosed gynecologic malignancy (uterine, cervical, ovarian, primary peritoneal, vulvar, or vaginal) and undergoing chemotherapy * own a smartphone or tablet with ability to download cognitive training application * and age \>21 years old Exclusion criteria include: * medical diagnosis of dementia * significant underlying mental diagnoses for which they are on more than 1 medication for (patients with depression or anxiety on single-agent therapy will be able to participate * age \<21
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer-related cognitive difficulties are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cholesterol drug simvastatin joins chemo in breast cancer trial
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues
- New PET tracer aims to light up hidden cancer targets
- Can pulsed radiation extend life in metastatic cervical cancer?